ReviewInternational journal of endocrinology2026
Adipokine in Metabolic Liver Disease: Adipo-Brain-Liver Cross talk.
Review in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Adipokines play a key role in the interaction between the brain, liver, and adipose tissue. In this review, we selected adipokines with wide central receptor expression and summarized their indirect regulation on liver metabolism by acting on specific neurons and inducing neuropeptide production. Methods: A thorough PubMed search of peer-reviewed studies was conducted using suitable keywords. Results: Since adipokine receptors could be expressed in both the brain and liver, adipokines could regulate energy homeostasis either directly through receptors expressed in the liver or indirectly by acting centrally. The latter can be achieved by acting in brain regions that have neural projections to the liver. Furthermore, growing evidence demonstrates that adipokines, while playing the above roles, are closely linked to the progression of nonalcoholic fatty liver disease (NAFLD). Conclusions: This review revealed that adipose tissue could be involved in regulating liver-brain cross talk during energy regulation and metabolism-related diseases. In addition, we focused on the relationship between the mechanism of action of these adipokines and the progression of metabolic syndromes such as NAFLD and explored their potential as novel biomarkers and therapeutic targets for the treatment of metabolic diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.